A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Key Points
Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing.
By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.
The trade amounted to just under 1.5% of the fund's total 13F assets.
Post-trade stake: 1,375,000 shares valued at $34.95 million.
Immunovant now sits at about 2% of the portfolio — notable, but outside the fund's top five.
- 10 stocks we like better than Immunovant ›
On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant (NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing.
- Logos bought 1,100,000 additional shares of Immunovant, a transaction estimated at $24.5 million based on average quarterly closing prices.
- The full position grew by roughly $6.1 million in total value over the quarter, reflecting both the new shares and price movement in the stock.
- Logos finished the quarter holding 1,375,000 Immunovant shares, valued at roughly $34.95 million which represents 2.11% of the fund’s AUM, placing it outside the fund’s top five holdings
What happened
According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Logos Global Management LP increased its position in Immunovant by 1,100,000 shares during the fourth quarter of 2025. The estimated transaction value was $24.4 million, based on the average closing price in the quarter. The value of the stake at quarter-end rose by $6.1 million, a figure that includes both trading and market price effects.
What else to know
- After the buy Immunovant accounts for 2.11% of the fund’s 13F assets under management (AUM)
- Top holdings after the filing:
- NASDAQ:RVMD: $238.50 million (14.4% of AUM)
- NASDAQ:PRAX: $110.53 million (6.7% of AUM)
- NASDAQ:IDYA: $108.03 million (6.5% of AUM)
- NASDAQ:OLMA: $80.22 million (4.9% of AUM)
- NASDAQ:CDTX: $68.48 million (4.1% of AUM)
- As of March 13 2026, shares of Immunovant were priced at $24.72, up 29.3% over the past year and outperforming the S&P 500 by 10.58%.
Company Overview
| Metric | Value |
|---|---|
| Price (as of market close 3/13/26) | $24.70 |
| Market Capitalization | $5.03 billion |
| Net Income (TTM) | ($464.20 million) |
| 1-Year Price Change | 29.24% |
Company Snapshot
- Immunovant is a subsidiary of Roivant Sciences (NASDAQ: ROIV) focused on monoclonal antibody therapeutics for autoimmune diseases.What this transaction means for investors
- Its lead candidate, batoclimab, has completed Phase III trials in myasthenia gravis and is in ongoing Phase III trials for thyroid eye disease, with results expected in the first half of 2026.
- The company has no approved products yet — revenue depends entirely on successful clinical and regulatory outcomes.
Immunovant is advancing batoclimab across multiple autoimmune indications, with no approved products yet and a regulatory path that hinges on ongoing Phase III outcomes.
What This Transaction Means for Investors
Logos Global Management is a San Francisco-based, healthcare-focused hedge fund running a concentrated, research-driven book in life sciences and biotech. This isn't a generalist fund dipping into the sector — it's the kind of firm that does deep scientific and regulatory diligence before sizing up a position.
The Immunovant buy is notable for its scale. Logos nearly quintupled its stake, adding 1.1 million shares for an estimated $24.5 million and bringing its total to roughly $35 million. That's a meaningful commitment: Immunovant now sits at about 2% of AUM, up from 0.4% — a shift that carries real weight in a concentrated book.
For individual investors, a move like this from a specialist healthcare fund is worth treating as a research prompt rather than a buy signal. Clinical-stage biotech carries real binary risk, and institutional conviction here is usually the product of diligence retail investors don't have direct access to. The more useful takeaway is simply that a fund that lives in this space saw enough to add aggressively — why exactly, and how it fits their broader strategy, is hard to know without explicit statements from them. What investors can watch is the batoclimab thyroid eye disease readout, with topline data from both Phase 3 TED studies expected concurrently in the first half of 2026. That's the next concrete event that will shape Immunovant's regulatory path.
Should you buy stock in Immunovant right now?
Before you buy stock in Immunovant, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Immunovant wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $514,000!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,105,029!*
Now, it’s worth noting Stock Advisor’s total average return is 930% — a market-crushing outperformance compared to 187% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 15, 2026.
Seena Hassouna has no position in any of the stocks mentioned. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy.
Recommended Articles
